Another Potential Breakthrough: 3-in-1 Antibody Shows Promise
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/in Artificial Intelligence, Not PCa related/by MaxBreakthrough discovery (in vitro): selective MMP7 inhibitor for cancer treatment
/in Not PCa related, Preclinical Research/by MaxBreaking Barriers: FDA Approval of Tecelra Marks a New Era for TCR Therapy in Solid Tumors
/in Not PCa related/by MaxNot related to prostate cancer but really interesting: allogenic CAR-T is getting good results!
/in Not PCa related/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026